<DOC>
	<DOC>NCT00989521</DOC>
	<brief_summary>PUR003 is an inhaled substance that is proposed to assist in the treatment of asthma. Study objectives are to : 1. to evaluate the safety of PUR003 in subjects with asthma, and 2. to evaluate the efficacy of PUR003 in assisting the treatment of asthma.</brief_summary>
	<brief_title>Effect of PUR003 on Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Bronchial Diseases</mesh_term>
	<criteria>1. Signed written informed consent. 2. Ability and willingness to return to the outpatient clinic for repeated clinic visits and complete all assessments. 3. Adult male or female subject, 1860 years of age. 4. Stable, mild asthma not requiring any medical treatment other than short acting inhaled bronchodilators, as needed. 5. No smoking within six months prior to entry 6. Must be medically stable. 7. Female subjects must have a negative pregnancy test 8. Subjects of child bearing potential should be sexually inactive (abstinent) for 14 days prior to the first dose of study medication or using an acceptable form of birth control methods. 1. History or presence of significant coexisting chronic diseases. 2. History of asthma exacerbations or upper or lower respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) within four weeks of first visit. 3. Pregnancy, breastfeeding. 4. Abused alcohol or illicit drugs that required treatment. 5. Participated in any other investigational drug evaluation within last 30 days. 6. Scheduled to have elective or invasive medical intervention, procedure, or surgery within 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>bronchial diseases</keyword>
	<keyword>lung diseases</keyword>
	<keyword>bronchitis</keyword>
	<keyword>respiratory tract diseases</keyword>
</DOC>